Forskning
Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital
Udgivet

Challenges in Cardiovascular Pharmacogenomics Implementation: A viewpoint from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Harvard

Magavern, EF, Kaski, JC, Turner, RM, Drexel, H, Janmohamed, A, Scourfield, A, Burrage, D, Floyd, CN, Adeyeye, E, Tamargo, J, Lewis, BS, Kjeldsen, KP, Niessner, A, Wassmann, S, Sulzgruber, P, Borry, P, Agewall, S, Semb, AG, Savarese, G, Pirmohamed, M & Caulfield, MJ 2022, 'Challenges in Cardiovascular Pharmacogenomics Implementation: A viewpoint from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy', European heart journal. Cardiovascular pharmacotherapy, bind 8, nr. 1, s. 100-103. https://doi.org/10.1093/ehjcvp/pvab063

APA

Magavern, E. F., Kaski, J. C., Turner, R. M., Drexel, H., Janmohamed, A., Scourfield, A., Burrage, D., Floyd, C. N., Adeyeye, E., Tamargo, J., Lewis, B. S., Kjeldsen, K. P., Niessner, A., Wassmann, S., Sulzgruber, P., Borry, P., Agewall, S., Semb, A. G., Savarese, G., ... Caulfield, M. J. (2022). Challenges in Cardiovascular Pharmacogenomics Implementation: A viewpoint from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. European heart journal. Cardiovascular pharmacotherapy, 8(1), 100-103. https://doi.org/10.1093/ehjcvp/pvab063

CBE

Magavern EF, Kaski JC, Turner RM, Drexel H, Janmohamed A, Scourfield A, Burrage D, Floyd CN, Adeyeye E, Tamargo J, Lewis BS, Kjeldsen KP, Niessner A, Wassmann S, Sulzgruber P, Borry P, Agewall S, Semb AG, Savarese G, Pirmohamed M, Caulfield MJ. 2022. Challenges in Cardiovascular Pharmacogenomics Implementation: A viewpoint from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. European heart journal. Cardiovascular pharmacotherapy. 8(1):100-103. https://doi.org/10.1093/ehjcvp/pvab063

MLA

Vancouver

Author

Magavern, E F ; Kaski, J C ; Turner, R M ; Drexel, H ; Janmohamed, A ; Scourfield, A ; Burrage, D ; Floyd, C N ; Adeyeye, E ; Tamargo, J ; Lewis, B S ; Kjeldsen, Keld Per ; Niessner, A ; Wassmann, S ; Sulzgruber, P ; Borry, P ; Agewall, S ; Semb, A G ; Savarese, G ; Pirmohamed, M ; Caulfield, M J. / Challenges in Cardiovascular Pharmacogenomics Implementation : A viewpoint from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy. I: European heart journal. Cardiovascular pharmacotherapy. 2022 ; Bind 8, Nr. 1. s. 100-103.

Bibtex

@article{b153f32ab908419daf7d7233120f01c9,
title = "Challenges in Cardiovascular Pharmacogenomics Implementation: A viewpoint from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy",
abstract = "Pharmacogenomics promises to advance cardiovascular therapy, but there remain pragmatic barriers to implementation. These are particularly important to explore within Europe, as there are differences in the populations, availability of resources, and expertise, as well as in ethico-legal frameworks. Differences in healthcare delivery across Europe present a challenge, but also opportunities to collaborate on pharmacogenomics implementation. Clinical workforce upskilling is already in progress but will require substantial input. Digital infrastructure and clinical support tools are likely to prove crucial. It is important that widespread implementation serves to narrow rather than widen any existing gaps in health equality between populations. This viewpoint supplements the working group position paper on cardiovascular pharmacogenomics to address these important themes.",
author = "Magavern, {E F} and Kaski, {J C} and Turner, {R M} and H Drexel and A Janmohamed and A Scourfield and D Burrage and Floyd, {C N} and E Adeyeye and J Tamargo and Lewis, {B S} and Kjeldsen, {Keld Per} and A Niessner and S Wassmann and P Sulzgruber and P Borry and S Agewall and Semb, {A G} and G Savarese and M Pirmohamed and Caulfield, {M J}",
note = "{\textcopyright} The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology.",
year = "2022",
month = jan,
day = "5",
doi = "10.1093/ehjcvp/pvab063",
language = "English",
volume = "8",
pages = "100--103",
journal = "European Heart Journal - Cardiovascular Pharmacotherapy",
issn = "2055-6837",
publisher = "Oxford University Press",
number = "1",

}

RIS

TY - JOUR

T1 - Challenges in Cardiovascular Pharmacogenomics Implementation

T2 - A viewpoint from the European Society of Cardiology Working Group on Cardiovascular Pharmacotherapy

AU - Magavern, E F

AU - Kaski, J C

AU - Turner, R M

AU - Drexel, H

AU - Janmohamed, A

AU - Scourfield, A

AU - Burrage, D

AU - Floyd, C N

AU - Adeyeye, E

AU - Tamargo, J

AU - Lewis, B S

AU - Kjeldsen, Keld Per

AU - Niessner, A

AU - Wassmann, S

AU - Sulzgruber, P

AU - Borry, P

AU - Agewall, S

AU - Semb, A G

AU - Savarese, G

AU - Pirmohamed, M

AU - Caulfield, M J

N1 - © The Author(s) 2021. Published by Oxford University Press on behalf of the European Society of Cardiology.

PY - 2022/1/5

Y1 - 2022/1/5

N2 - Pharmacogenomics promises to advance cardiovascular therapy, but there remain pragmatic barriers to implementation. These are particularly important to explore within Europe, as there are differences in the populations, availability of resources, and expertise, as well as in ethico-legal frameworks. Differences in healthcare delivery across Europe present a challenge, but also opportunities to collaborate on pharmacogenomics implementation. Clinical workforce upskilling is already in progress but will require substantial input. Digital infrastructure and clinical support tools are likely to prove crucial. It is important that widespread implementation serves to narrow rather than widen any existing gaps in health equality between populations. This viewpoint supplements the working group position paper on cardiovascular pharmacogenomics to address these important themes.

AB - Pharmacogenomics promises to advance cardiovascular therapy, but there remain pragmatic barriers to implementation. These are particularly important to explore within Europe, as there are differences in the populations, availability of resources, and expertise, as well as in ethico-legal frameworks. Differences in healthcare delivery across Europe present a challenge, but also opportunities to collaborate on pharmacogenomics implementation. Clinical workforce upskilling is already in progress but will require substantial input. Digital infrastructure and clinical support tools are likely to prove crucial. It is important that widespread implementation serves to narrow rather than widen any existing gaps in health equality between populations. This viewpoint supplements the working group position paper on cardiovascular pharmacogenomics to address these important themes.

U2 - 10.1093/ehjcvp/pvab063

DO - 10.1093/ehjcvp/pvab063

M3 - Journal article

C2 - 34463331

VL - 8

SP - 100

EP - 103

JO - European Heart Journal - Cardiovascular Pharmacotherapy

JF - European Heart Journal - Cardiovascular Pharmacotherapy

SN - 2055-6837

IS - 1

ER -

ID: 67446039